This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser.
Print Document
View Excel Document
Cover
Document and Entity Information
Financial Statements
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS (Parenthetical)
CONSOLIDATED STATEMENTS OF OPERATIONS
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)
CONSOLIDATED STATEMENTS OF CASH FLOWS
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)
Notes to Financial Statements
Organization and Significant Accounting Policies
Investment in Regulus Therapeutics Inc.
Investments
Long-Term Obligations and Commitments
Stockholders' Equity
Income Taxes
Collaborative Arrangements and Licensing Agreements
Concentration of Business Risk
Employment Benefits
Legal Proceedings
Quarterly Financial Data (Unaudited)
Accounting Policies
Organization and Significant Accounting Policies (Policies)
Notes Tables
Organization and Significant Accounting Policies (Tables)
Investments (Tables)
Long-Term Obligations and Commitments (Tables)
Stockholders' Equity (Tables)
Income Taxes (Tables)
Concentration of Business Risk (Tables)
Quarterly Financial Data (Unaudited) (Tables)
Notes Details
Organization and Significant Accounting Policies, Revenue Recognition (Details)
Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details)
Organization and Significant Accounting Policies, Cash, Cash Equivalents and Short-term Investments and Inventory Valuation (Details)
Organization and Significant Accounting Policies, Property, Plant and Equipment (Details)
Organization and Significant Accounting Policies, Licenses and Long-lived Assets (Details)
Organization and Significant Accounting Policies, Consolidation of Variable Interest Entities (Details)
Organization and Significant Accounting Policies, Stock-based Compensation (Details)
Organization and Significant Accounting Policies, Accumulated Other Comprehensive Income (Details)
Organization and Significant Accounting Policies, Convertible Debt (Details)
Organization and Significant Accounting Policies, Fair Value Measurements on a Recurring Basis (Details)
Organization and Significant Accounting Policies, Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (Details)
Investment in Regulus Therapeutics Inc. (Details)
Investments (Details)
Investments, Investment Holdings (Details)
Long-Term Obligations and Commitments (Details)
Long-Term Obligations and Commitments, Annual debt and other obligation maturities (Details)
Long-Term Obligations and Commitments, Leased Assets (Details)
Stockholders' Equity, Preferred and Common Stock (Details)
Stockholders' Equity, Stock Plans (Details)
Stockholders' Equity, Stock Option Activity (Details)
Stockholders' Equity, Restricted Stock Unit Activity (Details)
Stockholders' Equity, Stock-based Compensation Expense (Details)
Stockholders' Equity, Stock-based Valuation Information (Details)
Stockholders' Equity, Warrants (Details)
Income Taxes, Provision for Income Taxes (Details)
Income Taxes, Reconciliation of Effective Tax Rate (Details)
Income Taxes, Deferred Tax Assets and Liabilities (Details)
Income Taxes, Tax Credit Carryforward (Details)
Income Taxes, Gross Unrecognized Tax Benefits (Details)
Collaborative Arrangements and Licensing Agreements, Pharmaceutical Alliances and Licensing - AstraZeneca (Details)
Collaborative Arrangements and Licensing Agreements, Pharmaceutical Alliances and Licensing - Biogen Idec (ISIS-SMN) (Details)
Collaborative Arrangements and Licensing Agreements, Pharmaceutical Alliances and Licensing - Biogen Idec (ISIS-DMPK) (Details)
Collaborative Arrangements and Licensing Agreements, Pharmaceutical Alliances and Licensing - Biogen Idec (Neurology) (Details)
Collaborative Arrangements and Licensing Agreements, Pharmaceutical Alliances and Licensing - Biogen Idec (Strategic Neurology) (Details)
Collaborative Arrangements and Licensing Agreements, Pharmaceutical Alliances and Licensing - Genzyme Corporation (Details)
Collaborative Arrangements and Licensing Agreements, Pharmaceutical Alliances and Licensing - GlaxoSmithKline (Details)
Collaborative Arrangements and Licensing Agreements, Pharmaceutical Alliances and Licensing - Janssen Biotech, Inc. (Details)
Collaborative Arrangements and Licensing Agreements, Pharmaceutical Alliances and Licensing - Roche (Details)
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Achaogen, Inc. (Details)
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Alnylam Pharmaceuticals, Inc. (Details)
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Antisense Therapeutics Limited (Details)
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Atlantic Pharmaceuticals Limited (Details)
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Excaliard Pharmaceuticals, Inc. (Details)
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - OncoGenex Technologies Inc. (Details)
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Regulus Therapeutics Inc. (Details)
Collaborative Arrangements and Licensing Agreements, External Project Funding (Details)
Collaborative Arrangements and Licensing Agreements, Technology and Intellectual Property Sale and Licensing Agreements (Details)
Concentration of Business Risk (Details)
Employment Benefits (Details)
Quarterly Financial Data (Unaudited) (Details)
All Reports
Rendering Log